The drug is being evaluated on its safety, tolerability and pharmacokinetics of intravitreal single-rising doses and multiple doses as a potential treatment for GA.
According to a press release from CDR-Life, BI 771716 is licensed to Boehringer Ingelheim and is a “highly specific antibody fragment of reduced size enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology.”1
Christian Leisner, PhD, Chief Executive Officer at CDR-Life, commented on the initiation of the trial in the press release from the company.
“This milestone marks CDR-Life's emergence as a clinical-stage company and underscores the ability of our platform to generate molecules that may one day bring life-changing treatments to patients,” said Leisner. “We look forward to the continued development of BI 771716 as it progresses through the clinic.”1
The Phase 1 study evaluates the safety, tolerability, and pharmacokinetics of intravitreal single-rising doses and multiple doses of BI 771716 as a potential treatment for GA.1